Situated on plot 2 of the Adanac Health and Innovation Campus in Southampton, the new multi-use facility, being funded by Macquarie Asset Management on behalf of the retirement specialist, Just Group plc, will comprise an Aseptic Pharmacy and Sterile Services Department (SSD), with further flexible expansion space. The Aseptic Pharmacy will act as an MHRA-licensed pharmacy, with sterile medicines manufactured for UHS and other NHS providers in the region. Meanwhile, the SSD will sterilise surgical tools and equipment for use by UHS; these services will be delivered at the new location by strategic provider, IHSS.
UHS is one of England’s largest acute teaching Trusts, and says it experiences a very high demand on its geographically constrained site. By working with Prime plc through the Southampton Commercial Estates Development Partnership (CEDP), the Trust has been able to unlock a number of complex estate challenges. These new facilities will be the latest in a series of developments designed to create more space for the Trust to expand. Previous development on the hospital site has produced a new entrance, retail space, and staff car park. The partners then worked together to create Adanac Health and Innovation Campus, providing additional expansion space with good proximity to the hospital, and easy access to the motorway network. To date, a multi-storey park and ride car park serving the hospital and Costa Coffee have been delivered at the new campus, with a remaining three plots still to be developed.
This is the latest scheme between Willmott Dixon and Prime. Recently the two organisations worked together to deliver a 600+ space multi-storey car park at Dorset County Hospital, creating important parking provision for the Trust’s staff, patients, and visitors. The company is also one of the UK’s largest constructors of healthcare space.
James Allen, Chief Pharmacist at UHS, said: “We are delighted to be working alongside Wilmott Dixon and Prime in the construction of our new pharmacy aseptic production facility. This state-of-the-art facility will be a significant leap forward in our capacity to produce sterile, pre-prepared medicines. As an MHRA-licensed unit, the facility will utilise advances in automation to produce products at scale, enhancing the capacity of patient pathways in UHS and NHS Trusts in Hampshire and neighbouring healthcare systems.”